glp-1 drug GLP1 Use For Weight Loss Has Soared Costing Billions Poll: 1 in 8 Adults

doi: 10.1016/j.jhep.2023.07.033

However, oral administration is gaining traction, led by Rybelsus, the first oral GLP-1 approved by the FDA

However, conflicting evidence highlights context-dependent risks, such as early DR worsening in poorly controlled glycemic states

The FDA, ADA, and AACE do not support the use of this combination in patients with type 2 diabetes

Compounded GLP-1s have not been evaluated by the FDA, but side effects are expected to be similar to other GLP-1-based medications reviewed by the FDA, which have the following side effects: nausea, diarrhea, vomiting, constipation, abdominal (stomach) pain, headache, fatigue, dyspepsia (indigestion), dizziness, abdominal distension, eructation (belching), hypoglycemia (low blood sugar), flatulence (gas buildup), gastroenteritis (an intestinal infection), and gastroesophageal reflux disease (a type of digestive disorder)

But for now, we have new options that are safe, appear to reduce complications, and are very effective